1. Trang chủ
  2. » Luận Văn - Báo Cáo

Báo cáo khoa học: "Association between intratumoral lymphatic microvessel density (LMVD) and clinicopathologic features in endometrial cancer: a retrospective cohort study" pdf

7 312 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 7
Dung lượng 428,89 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

Few data on the influence of intratumoral lymphatic microvessel density LMVD on survival in endometrial cancer are available.. Our aim was to assess the intratumoral LMVD of endometrial

Trang 1

R E S E A R C H Open Access

Association between intratumoral lymphatic

microvessel density (LMVD) and clinicopathologic features in endometrial cancer: a retrospective cohort study

Lecy Kawamura1, Filomena M Carvalho2*, Bernardo GL Alves2, Carlos E Bacchi3, Joao Carlos Sampaio Goes4, Marcelo Alvarenga Calil4, Edmund C Baracat1, Jesus P Carvalho1

Abstract

Background: Lymph node metastasis in endometrial cancer significantly decreases survival rate Few data on the influence of intratumoral lymphatic microvessel density (LMVD) on survival in endometrial cancer are available Our aim was to assess the intratumoral LMVD of endometrial carcinomas and to investigate its association with classical pathological factors, lymph node metastasis and survival

Methods: Fifty-seven patients with endometrial carcinoma diagnosed between 2000 and 2008 underwent

complete surgical staging and evaluation of intratumoral LMVD and other histologic variables Lymphatic

microvessels were identified by immunohistochemical staining using monoclonal antibody against human

podoplanin (clone D2-40) and evaluated by counting the number of immunostained lymphatic vessels in 10 hot spot areas at 400× magnification The LMVD was expressed by the mean number of vessels in these 10 hot spot microscopic fields We next investigated the association of LMVD with the clinicopathologic findings and prognosis Results: The mean number of lymphatic vessels counted in all cases ranged between 0 and 4.7 The median value

of mean LMVD was 0.5, and defined the cut-off for low and high LMVD We identified low intratumoral LMVD in

27 (47.4%) patients and high LMVD in 30 (52.6%) patients High intratumoral LMVD was associated with lesser miometrial and adnaexal infiltration, lesser cervical and peritoneal involvement, and fewer fatal cases Although there was lower lymph node involvement among cases with high LMVD, the difference did not reach significance

No association was seen between LMVD and FIGO staging, histological type, or vascular invasion On the other hand, low intratumoral LMVD was associated with poor outcome Seventy-five percent of deaths occurred in patients with low intratumoral LMVD

Conclusion: Our results show association of high intratumoral LMVD with features related to more localized

disease and better outcome We discuss the role of lymphangiogenesis as an early event in the endometrial

carcinogenesis

Background

Endometrial cancer is the most frequent gynecologic

malignancy in the western world The death rate has

increased during the most recent decades, probably due to

an increase in life span and coexisting medical

comorbidities [1] The most important prognostic factors

in endometrial cancer are histological type, grade, lymph node status, deep myometrial invasion, and stage [2,3] Approximately 72% of endometrial cancers are stage I, 12% stage II, 13% stage III, and 3% stage IV(1) Five year survival is about 90% in disease confined to the uterus, but drops to 60% when lymph nodes are positive [4] Lymph node metastasis is a complex, multi-step biological process initialized by tumor cells, involving stroma invasion, new

* Correspondence: filomena@usp.br

2

Department of Pathology of Faculdade de Medicina da Universidade de

São Paulo, Sao Paulo (SP), Brazil

Full list of author information is available at the end of the article

© 2010 Kawamura et al; licensee BioMed Central Ltd This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and

Trang 2

lymphatic vessel formation, and spread through lymphatic

vessels to lymph node Understanding how cancer cells

gain access to lymphatic channels and develop metastases

is of great interest for development of new therapeutic

strategies targeted against members of the signaling

path-ways involved in the lymphangiogenesis process

The growth of lymphatic vessels largely depends on

many growth factors, such as vascular endothelial

growth factor-C and -D (VEGF-C and VEGF-D), platelet

derived growth factor-BB (PDGF-BB) and hepatocyte

growth factor[5] However, in cancer, these known

lym-phangiogenic factors lead to simultaneous stimulation of

angiogenesis and lymphangiogenesis [6] Lymphatic

microvessel density (LMVD) is one of the ways to

evalu-ate lymphangiogenesis It was poor studied due to the

difficulties associated with detecting and characterizing

lymphatic markers Currently, several molecules

specifi-cally expressed in lymphatic endothelial cells, such as

podoplanin, LYVE1, and the homeobox gene prox-1,

have enabled a more precise study of the lymphatic

vas-culature and the molecular mechanisms involved in

lymphangiogenesis [7] LMVD has been investigated in

many tumors, particularly those characterized by

lym-phatic dissemination, such as cervical carcinomas [8-10],

but there are few studies that have evaluated LMVD in

endometrial carcinomas, and results have been

conflict-ing [11,12]

Therefore, the aim of this retrospective study was to

evaluate the relationship between intratumoral LMVD,

as well as other histologic variables, and the incidence

of lymph node metastasis and overall survival of patients

with endometrial cancer following hysterectomy and

lymph node dissection

Methods

Patients

This study retrospectively analyzed patients with

endo-metrial cancer treated at the Instituto Brasileiro de

Con-trole do Cancer (IBCC), a reference Cancer Center in

São Paulo, Brazil, between 2000 and 2008 This cohort

of 57 patients included 28 (49.1%) with stage I disease, 4

(7.0%) with stage II disease, 22 (38.5%) with stage III

disease, and 3 (5.2%) with stage IV disease, classified

according to the 2009 revised International Federation

of Gynecology and Obstetrics (FIGO) system [13] Age

of patients ranged from 46 to 89 years (67.4 ± 10.27 y)

All patients had undergone surgical staging

hysterect-omy with a sample of pelvic lymph nodes The number

of lymph nodes excised ranged from 3 to 49 (21.5 ±

12.44), and they were positive in 22 (38.6%) and negative

in 35 (61.4%) cases Paraortic lymph nodes were

assessed in 27 cases and nine of them were involved by

the neoplasia The follow-up ranged from 6 to 144

months (mean 39.54 ± 29.98 months) Twelve patients

died of their disease between 6 and 108 months after the diagnosis (median 21.5 months) Data about myo-metrial, cervical, adnexal and peritoneal involvement, were retrieved from the medical records This study was approved by the Department of Obstetrics and Gynecol-ogy Scientific Committee of the Faculdade de Medicina

da Universidade de São Paulo, by the Ethical Committee for Research Projects of the Hospital das Clinical da Faculdade de Medicina da Universidade de São Paulo (Comissão de Ética para Análise de Pesquisa - CAPPesq) (process number 0728/08), and by the Ethical Commit-tee for Research of the Instituto Brasileiro de Controle

do Cancer

Tumor Specimens Tumor slides were reviewed independently by two pathologists and were classified according to the criteria

of the World Health Organization (WHO) Classification

of Tumors [14] The Vancouver system was applied to classify the tumors in low and high grades A tumor was considered high grade if it showed at least two of these criteria: 1) predominantly papillary or solid growth pat-tern, 2) 6 or more mitotic figures/10 high power fields,

or 3) severe nuclear atipia [15] Peritumoral lymphovas-cular space invasion (LVSI) was also evaluated for all cases in the whole histological sections A representative peripheral area of the tumor was selected for the con-struction of tissue microarray blocks and immunohisto-chemical study

Construction of tissue microarray (TMA) blocks The tumor areas selected in the slides were marked in the corresponding paraffin donor blocks and one cylin-der of material (2.0 mm in diameter) was punched from each case and mounted into recipient paraffin blocks at

1 mm intervals using a precision microarray instrument (Beecher Instruments, Silver Spring, MD) A grid system was established such that each core had an x and y coordinate reference for sample identification Blocks were sealed at 60°C for 10 m Three μm sections from each TMA block were then prepared using standard techniques and mounted on Starfrost® slides The first histological sections were stained by hematoxilin-eosin and examined to be sure the correct areas were included

Immunohistochemistry analysis Histological sections (3 μm) from TMA blocks were quenched with 3% hydrogen peroxide solution in phos-phate-buffered saline (PBS; Sigma, St Louis, MO) for 20

m to block endogenous peroxidase activity After several washes in PBS, sections were heated in a microwave (Electrolux, 900 W) for 15 m in 0.01 M citrate buffer,

pH 6.0 for antigen retrieval, then cooled at RT for 20 m

Trang 3

Sections were then incubated overnight with a 1:400

dilution of monoclonal antibody against human

podo-planin (clone D2-40, Dako, Carpinteria, CA) Podopodo-planin

is a glycoprotein specifically expressed by lymphatic

endothelial cells In those tumor sections with negative

podoplanin staining, adjacent normal-appearing

lympha-tic endothelial cells served as positive internal controls

Quantification of lymphatic microvessel density

Stained TMA histologic sections were analyzed using

standard light microscopy (Nikon, Eclipse 200) Under

low magnification, the most vascularized intratumoral

areas were identified We counted the number of

immu-nostained lymphatic vessels found in 10 hot spot areas

at 400× magnification Only vessels exhibiting typical

morphology (lumen) were considered lymphatic

micro-vessels (Figure 1) The LMVD for each case was

expressed by the mean value (total number of vessels in

10 hot spot microscopic fields/10) The median value of

all the mean LMVD was the cutoff to divide tumors in

high or low LMVD, as suggested by Hall et al.[16]

Statistical analyses

The association between categorical variables and lymph

node status and survival were evaluated using Pearson’s

Chi-square test Kaplan & Meier method was used to

produce time life tables and survival curves

A p-value less than 0.05 was considered significant

The software used was Epi Infotm, Version 3.5.1 [17]

Results

The tumors were classified as endometrioid (44 cases,

77.2%) and non-endometrioid classified as serous (6

cases, 10.5%), clear cell (4 cases, 7%), undifferentiated (2 cases, 3.5%), and mixed (1 case, 1.7%) The association between all the variables with lymph node status and patient death are summarized in Table 1 The mean number of lymphatic vessels counted in each patient’s tumor sample ranged from 0 to 4.7 The median value was 0.5 vessels and defined the value above and below which was considered high and low LMVD, respectively Low LMVD was found in 27 (47.4%) patients, and high LMVD was found in 30 (52.6%) patients We observed that low intratumoral LMVD was associated with poor outcome Seventy-five percent of deaths occurred in patients with low intratumoral LMVD (p = 0.031) The mean survival time observed in the group with low LMDV was 79 months (confidence interval [62 - 96 months]) and the mean survival time for high LMDV group was 129 months (confidence interval [113 - 145 months]) The difference was significant at 5% level The survival curves for both LMDV groups are presented at Figure 2

Low LMVD was also associated with miometrial and adnaexal infiltration, cervical and peritoneal involve-ment Patients below 70 years presented higher LMVD (21/33, 63.3%) than older patients (9/24, 37.5%) although the difference did not reach statistical signifi-cance No association was seen between LMVD and FIGO staging, histological type, vascular invasion, or lymph node involvement (Table 2)

Positive lymph nodes were significantly associated with histological grade (p = 0.001), vascular invasion (p = 0.017), FIGO stage (p < 0.001), myometrial infiltration (p < 0,001), cervical infiltration (p = 0,023), adnaexal involvement (p = 0,023) and peritoneal involvement (p = 0,048) Besides LMVD, death was associated with histolo-gical type (p = 0.010), vascular invasion (p = 0.040), and lymph node involvement (p = 0.025) Mean survival time was 110 months (range of 84 - 135 months) for patients with negative lymph node involvement, and 69 months (range of 48 - 89 months) for patients with positive lymph nodes

Discussion

Lymphatic metastasis is one of the most important prognostic factors for survival of patients with endome-trial cancer as well as for other epithelial malignancies Many clinical and experimental data suggest that migra-tion of tumor cells into the lymph nodes is facilitated by lymphangiogenesis[18,19] Studies evaluating lymphatic neoformation and its role in tumoral migration are facilitated by the recent identification of lymphangio-genic factors and their receptors, and by lymphatic vas-cular markers [5]

The most commonly used markers for immunohisto-chemistry identification of lymphatic endothelial tissue

Figure 1 Immunohistochemistry staining of a histological

section of endometrioid carcinoma using D2-40 antibody

against podoplanin showing six lymphatic vessels After

counting 10 high power fields, the mean was calculated for each

case (Original magnification X400).

Trang 4

include the vascular endothelial growth factor receptor 3

(VEGFR-3), PROX-1, LYVE-1, and podoplanin [5]

Among these, podoplanin, a 38 kDa mucin-type

trans-membrane glycoprotein which is recognized by the

monoclonal antibody D2-40, is considered the most

reli-able marker with a high specificity and sensitivity [5] In

this study, we chose to evaluate podoplanin because it

was found to be expressed in lymphatic, but not blood

vascular endothelium [20], and is expressed in smaller

lymphatic vessels rather than larger ones [20], allowing

a more sensitive identification of lymphangiogenesis

We then considered which compartment (intra or

peritumoral) to evaluate for lymphangiogenesis in this

study, as this is a source of great controversy in the

lit-erature Since our knowledge of lymphangiogenesis in

different types of cancer is still limited, we decided that

it would be worthwhile to begin accumulating data We

believe that a better understanding of the role of

lym-phangiogenesis in tumoral dissemination will only be

achieved after contributions from different researchers groups

In this study, we evaluated LMVD in the intratumoral compartment using podoplanin as the lymphatic marker Vascular density was determined by direct counting of vessels in 10 high power microscope fields Although our study is limited by the fact that LMVD was assessed only in TMA sections, the area of the tumor that was investigated was rigorously chosen considering fixation conditions of the specimen, morphology of the tumor, and the peripheral localization of the sample Besides, our cores had 2.0 mm in diameter, bigger than the con-ventional cores

LMVD has been studied in several cancers by various methods [21] There are few studies about LMVD in gynecological cancer Gombos et al [9] studied intra-and peritumoral LMVD using D2-40 immunohisto-chemistry in 111 cervical squamous cell carcinomas and correlated them with vascular endothelial growth factor

Table 1 Clinicopathological variables and association with lymph node status and outcome

negative n

positive n

alive n

dead n

1

p value (Chi-square of Pearson); 2

Intratumoral lymphatic microvessel density.

Trang 5

(VEGF)-C expression, clinicopathologic tumor features,

and outcome They found only high peritumoral LMVD

to be associated with poor overall survival Zhang et al.,

using LYVE-1 (lymphatic vessel endothelial hyaluronan

receptor-1) as the lymphatic marker, studied intra- and

peritumoral lymphatic vascular density in early-stage

invasive cervical carcinomas Both intravascular and

peritumoral high LMVD were associated with lymph

node metastasis [8] In a conflicting study, Birner et al

studied 95 cases of stage pTIb cervical carcinomas and

observed a more favorable prognosis among tumors

with high LMVD [10], a result that is similar to ours

LMVD studies in endometrial cancer are extremely

limited To investigate whether increased peritumoral

and intratumoral LMVD was a good prognostic factor

for nodal metastasis, Gao et al studied 102 patients

with endometrial carcinoma using LYVE-1 as the

lym-phatic marker [22] They found peritumoral but not

intratumoral high LMVD to be associated with lymph

node metastases Vandenput et al studied 62 patients

with endometrial carcinoma and found that neither

peri-tumoral nor intraperi-tumoral lymphangiogenesis determined

by podoplanin expression were related to prognosis [11]

Donughue et al evaluated lymphatic vessel density

(LVD) in 17 cases of endometrial carcinomas by

count-ing vessels expresscount-ing D2-40 Intratumoral LVD was

sig-nificantly increased when compared with endometrial

functionalis LVD, but not when compared with

endo-metrial basalis LVD They also observed a tendency

towards increased intratumoral LVD in grade 3 tumors

compared with grade 1 tumours [23] Other studies have documented lymphatic metastases independent of intratumoral lymphatic vessels suggesting that the intra-tumoral lymphatic vasculature is usually not functioning and only peritumoral lymphatic vessels conduct fluid and cells [24]

In our study, low LMVD was associated with poor outcome Seventy-five percent of deaths occurred in patients with low intratumoral LMVD compared with only 25% of deaths in patients with high LMVD (p = 0.031) In contrast, high LMVD was associated with favorable prognostic factors High LMVD tumors were associated with less myometrial infiltration > 50% (31%

vs 63%, p = 0.034), less cervical involvement (24.1% vs 53.8%, p = 0.023), and less peritoneal involvement (4%

vs 29.4%, p = 0.055) The explanation for this finding is not clear, but we can suppose that lymphangiogenesis is

an early event in tumor progression, when lymphatic vessels are still not functional Considering that higher LMVD was present in early anatomic tumors with no association with intrinsic tumors biological characteris-tics, as histological type or grade, we can suppose that this is an event related to the first steps of local interac-tion between tumor and microenvironment Besides, high LMVD was associated with favorable outcome, indicating that it might be clinically relevant However,

it must be pointed that the vascular density results from

a more complex biologic process that involves a cross-talk between tumor, vessels and host stroma Our results showed higher LMVD among tumor in the initial

Figure 2 Overall survival curve stratified for high and low intratumoral lymphatic microvessel density (LMVD).

Trang 6

steps of invasion (no extrauterine extension) and better

prognosis It is well known the role of normal lymphatic

vasculature in maintaining tissue homeostasis [25] The

lymphatic network must be investigated not only by its

anatomic density, as we did, but also functionally We

need intensive further investigation with more early

cases and adequate follow up, to explore the role of

vas-cular density in the tumoral progression These future

results may help elucidate pathways of

lymphangiogen-esis leading to identification of potential drug targets for

endometrial carcinomas Considering our preliminary

results, it is possible that the target would not be the lymphatic vessel itself, but some other molecules involved with its function

Conclusions

Our results show that high intratumoral LMVD is a characteristic of endometrial carcinomas with lesser extrauterine extension and is associated with better out-come However, further studies with larger series are needed to elucidate the biological meaning of these intriguing findings

Acknowledgements

We thank Antonio de Castro Bruni, M.S., for help with statistical analyses, and

Dr Eloa Muniz de Freitas Alves and Prof Joao Guidugli Neto for providing pathological materials This work was supported by grants of the Centro de Estudos do Instituto Brasileiro de Controle do Cancer.

Author details

1 Department of Obstetrics and Gynaecology of Faculdade de Medicina da Universidade de São Paulo, Sao Paulo (SP), Brazil 2 Department of Pathology

of Faculdade de Medicina da Universidade de São Paulo, Sao Paulo (SP), Brazil 3 Consultoria em Patologia, Botucatu (SP), Brazil 4 Instituto Brasileiro de Controle do Cancer, Sao Paulo (SP), Brazil.

Authors ’ contributions

LK collected the data and participated in pathological analyses of the samples and the drafting of the manuscript FMC conceived of the study, participated in its design and review the slides, and helped to the coordination and drafting of the manuscript BGLA reviewed all the histological samples and performed the immunohistochemical analyses CEB carried out the immunohistochemical reactions and helped their

interpretation JCSP, MAC and ECB participated in the design and the coordination, and helped to draft the manuscript JPC conceived of the study and participated in its design, coordination and drafting All authors read and approved the final manuscript.

Competing interests The authors declare that they have no competing interests.

Received: 13 June 2010 Accepted: 14 October 2010 Published: 14 October 2010

References

1 Sorosky JI: Endometrial cancer Obstet Gynecol 2008, 111:436-447.

2 Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC: Predictors of lymphatic failure in endometrial cancer Gynecol Oncol 2002, 84:437-442.

3 Prat J: Prognostic parameters of endometrial carcinoma Hum Pathol

2004, 35:649-662.

4 Hoekstra AV, Kim RJ, Small W Jr, Rademaker AW, Helenowski IB, Singh DK, Schink JC, Lurain JR: FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes Gynecol Oncol 2009, 114:273-278.

5 Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB: First international consensus on the methodology

of lymphangiogenesis quantification in solid human tumours Br J Cancer

2006, 95:1611-1625.

6 Cao Y: Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis Nat Rev Cancer 2005, 5:735-743.

7 Liersch R, Biermann C, Mesters RM, Berdel WE: Lymphangiogenesis in cancer: current perspectives Recent Results Cancer Res 2010, 180:115-135.

8 Zhang SQ, Yu H, Zhang LL: Clinical implications of increased lymph vessel density in the lymphatic metastasis of early-stage invasive cervical carcinoma: a clinical immunohistochemical method study BMC Cancer 2009, 9:64.

9 Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G: Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in

early-Table 2 Association between intratumoral lymphatic

microvessel density (LMVD) and clinicopathological

features

low n

high n

≥70 years 15 9 Histological type Endometrioid 19 25 0.396

Non-Endometrioid

Histological grade (Vancouver

system)

low 20 24 0.594

Myometrial infiltration <50% 10 20 0.034

>50% 17 9 Cervical infiltration no 12 22 0.047

Peritoneal involvement no 17 24 0.055

Lymph node involvement no 14 21 0.160

1

p value (Chi-square of Pearson).

Trang 7

stage squamous cell carcinoma of the uterine cervix Clin Cancer Res

2005, 11:8364-8371.

10 Birner P, Schindl M, Obermair A, Breitenecker G, Kowalski H, Oberhuber G:

Lymphatic microvessel density as a novel prognostic factor in

early-stage invasive cervical cancer Int J Cancer 2001, 95:29-33.

11 Vandenput I, Vanhove T, Calster BV, Gorp TV, Moerman P, Verbist G,

Vergote I, Amant F: The use of lymph vessel markers to predict

endometrial cancer outcome Int J Gynecol Cancer 2010, 20:363-367.

12 Stefansson IM, Salvesen HB, Akslen LA: Vascular proliferation is important

for clinical progress of endometrial cancer Cancer Res 2006, 66:3303-3309.

13 Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and

endometrium Int J Gynaecol Obstet 2009, 105:103-104.

14 Tavassoli FA, Deville A: Pathology & Genetics Tumours of Breast and Female

Genital Organs Lion: International Agency for Research on Cancer - IARC

Press 2003.

15 Alkushi A, Abdul-Rahman ZH, Lim P, Schulzer M, Coldman A, Kalloger SE,

Miller D, Gilks CB: Description of a novel system for grading of

endometrial carcinoma and comparison with existing grading systems.

Am J Surg Pathol 2005, 29:295-304.

16 Hall FT, Freeman JL, Asa SL, Jackson DG, Beasley NJ: Intratumoral

lymphatics and lymph node metastases in papillary thyroid carcinoma.

Arch Otolaryngol Head Neck Surg 2003, 129:716-719.

17 Epi Info Atlanta, GA: Centers for Disease Control and Prevention (CDC),

3.5.1 2008.

18 Alitalo K, Tammela T, Petrova TV: Lymphangiogenesis in development and

human disease Nature 2005, 438:946-953.

19 He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S,

Harding T, Jooss K, Takahashi T, Alitalo K: Vascular endothelial cell growth

factor receptor 3-mediated activation of lymphatic endothelium is

crucial for tumor cell entry and spread via lymphatic vessels Cancer Res

2005, 65:4739-4746.

20 Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K: Lymphangiogenesis

and cancer metastasis Nat Rev Cancer 2002, 2:573-583.

21 Sundar SS, Ganesan TS: Role of lymphangiogenesis in cancer J Clin Oncol

2007, 25:4298-4307.

22 Gao Y, Liu Z, Gao F, Meng XY: High density of peritumoral lymphatic

vessels is a potential prognostic marker of endometrial carcinoma: a

clinical immunohistochemical method study BMC Cancer 2010, 10:131.

23 Donoghue JF, Lederman FL, Susil BJ, Rogers PA: Lymphangiogenesis of

normal endometrium and endometrial adenocarcinoma Hum Reprod

2007, 22:1705-1713.

24 Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y,

Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK: Lymphatic

metastasis in the absence of functional intratumor lymphatics Science

2002, 296:1883-1886.

25 Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB,

Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K,

Rockson SG: Therapeutic lymphangiogenesis with human recombinant

VEGF-C FASEB J 2002, 16:1985-1987.

doi:10.1186/1477-7819-8-89

Cite this article as: Kawamura et al.: Association between intratumoral

lymphatic microvessel density (LMVD) and clinicopathologic features in

endometrial cancer: a retrospective cohort study World Journal of

Surgical Oncology 2010 8:89.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission

• Thorough peer review

• No space constraints or color figure charges

• Immediate publication on acceptance

• Inclusion in PubMed, CAS, Scopus and Google Scholar

• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

Ngày đăng: 09/08/2014, 03:22

TỪ KHÓA LIÊN QUAN

TÀI LIỆU CÙNG NGƯỜI DÙNG

TÀI LIỆU LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm